Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cefoxitin sodium -

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

gedeon richter plc - famotidine - tablets film-coated - 20mg

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

gedeon richter plc - famotidine - tablets film-coated - 40mg

Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - cefuroxime axetil -

Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - cefuroxime axetil -

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - cefoxitin sodium 1.18 g equivalent to cefoxitin 1.1 g (includes overage) - powder for injection - 1 g - active: cefoxitin sodium 1.18 g equivalent to cefoxitin 1.1 g (includes overage)

Eġittu - Ingliż - EDA (Egyptian Drug Authority)

misr - coated tablet - 500 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

orchidpharma inc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes, haemophilus influenzae (including beta- lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta- lactamase-producing strains). pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil tablets are generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime pro

Stati Uniti - Ingliż - NLM (National Library of Medicine)

gen-source rx - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes , haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains).  pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note:  only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of  streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxim

Stati Uniti - Ingliż - NLM (National Library of Medicine)

preferred pharmaceuticali inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - cefuroxime axetil tablets usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets usp for sinus infections caused by β-la